Hypofractionated Radiotherapy for Prostate Cancer: A Comparative Study of Clinical Outcomes and Dosimetry Between Proton and Photon Therapy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
118 patients with high-risk prostate cancer were treated with HFRT (70Gy in 28 fractions) between 2022-2024, receiving either intensity-modulated proton therapy (IMPT, n = 36) or photon therapy (VMAT, n = 82).
I · Intervention 중재 / 시술
long-term androgen deprivation therapy (ADT)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The identification of bladder V90% <11% as a planning constraint may guide treatment optimization. Further studies with longer follow-up are warranted to validate these benefits.
[BACKGROUND] Hypofractionated radiation therapy (HFRT) is increasingly accepted for prostate cancer.
- 표본수 (n) 36
APA
Wu CT, Chen WC, et al. (2025). Hypofractionated Radiotherapy for Prostate Cancer: A Comparative Study of Clinical Outcomes and Dosimetry Between Proton and Photon Therapy.. Cancer management and research, 17, 2589-2599. https://doi.org/10.2147/CMAR.S546959
MLA
Wu CT, et al.. "Hypofractionated Radiotherapy for Prostate Cancer: A Comparative Study of Clinical Outcomes and Dosimetry Between Proton and Photon Therapy.." Cancer management and research, vol. 17, 2025, pp. 2589-2599.
PMID
41190108 ↗
Abstract 한글 요약
[BACKGROUND] Hypofractionated radiation therapy (HFRT) is increasingly accepted for prostate cancer. This prospective study compared clinical outcomes, early prostate-specific antigen (PSA) dynamics, and dosimetry between proton and photon HFRT for high-risk prostate cancer.
[METHODS] A total of 118 patients with high-risk prostate cancer were treated with HFRT (70Gy in 28 fractions) between 2022-2024, receiving either intensity-modulated proton therapy (IMPT, n = 36) or photon therapy (VMAT, n = 82). All patients received long-term androgen deprivation therapy (ADT). Primary endpoints included biochemical control, PSA nadir at 6 months post-treatment, and genitourinary (GU) and gastrointestinal (GI) toxicities. Dosimetric comparisons were performed in silico.
[RESULTS] While biochemical control rates were comparable, a significantly higher proportion of patients receiving proton therapy achieved a PSA nadir <0.1 ng/mL within 6 months. Proton therapy was associated with reduced GU toxicity compared to photon therapy, based on assessments from both physicians and patients. Dosimetric analysis confirmed that proton therapy provided excellent target coverage with superior organ-at risk (bladder and rectum) sparing. We further identified dosimetric parameter to determine the cuff-off value for GU events. The data revealed the percentage volume of bladder receiving ≥90% prescribed dose (V90%) ≥11% has the predictive value for the development of grade ≥2 genitourinary toxicity.
[CONCLUSION] Two-year biochemical control was comparable between proton- and photon- based HFRT in high-risk prostate cancer. Proton therapy demonstrated improved early PSA kinetics and reduced GU toxicity, supported by favorable dosimetric profiles. The identification of bladder V90% <11% as a planning constraint may guide treatment optimization. Further studies with longer follow-up are warranted to validate these benefits.
[METHODS] A total of 118 patients with high-risk prostate cancer were treated with HFRT (70Gy in 28 fractions) between 2022-2024, receiving either intensity-modulated proton therapy (IMPT, n = 36) or photon therapy (VMAT, n = 82). All patients received long-term androgen deprivation therapy (ADT). Primary endpoints included biochemical control, PSA nadir at 6 months post-treatment, and genitourinary (GU) and gastrointestinal (GI) toxicities. Dosimetric comparisons were performed in silico.
[RESULTS] While biochemical control rates were comparable, a significantly higher proportion of patients receiving proton therapy achieved a PSA nadir <0.1 ng/mL within 6 months. Proton therapy was associated with reduced GU toxicity compared to photon therapy, based on assessments from both physicians and patients. Dosimetric analysis confirmed that proton therapy provided excellent target coverage with superior organ-at risk (bladder and rectum) sparing. We further identified dosimetric parameter to determine the cuff-off value for GU events. The data revealed the percentage volume of bladder receiving ≥90% prescribed dose (V90%) ≥11% has the predictive value for the development of grade ≥2 genitourinary toxicity.
[CONCLUSION] Two-year biochemical control was comparable between proton- and photon- based HFRT in high-risk prostate cancer. Proton therapy demonstrated improved early PSA kinetics and reduced GU toxicity, supported by favorable dosimetric profiles. The identification of bladder V90% <11% as a planning constraint may guide treatment optimization. Further studies with longer follow-up are warranted to validate these benefits.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.
- Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer.